Announcements Trials
Browse Landscape

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Observational 2Interventional 2

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Diabetes Mellitus 3Urinary Bladder Neoplasms 2Diabetes Mellitus, Type 2 2Pancreatic Neoplasms 1Neoplasms 1Metabolic Syndrome 1Inflammation 1Hypogonadism 1

Interventions

Dipeptidyl-Peptidase IV Inhibitors 4Sulfonylurea Compounds 3Metformin 3Vildagliptin 2Sodium-Glucose Transporter 2 Inhibitors 2Sitagliptin Phosphate 2Rosiglitazone 2Pioglitazone 2Glucagon-Like Peptide-1 Receptor Agonists 2voglibose 1somapacitan 1semaglutide 1saxagliptin 1repaglinide 1miglitol 1metahexamide 1meglitinide 1glymidine 1glisoxepide 1gliquidone 1glimepiride 1glibornuride 1empagliflozin 1desaminopancreozymin octapeptide 1alogliptin 1Urine Specimen Collection 1Troglitazone 1Tolbutamide 1Tolazamide 1Thiazolidinediones 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Observational × Diabetes Mellitus, Type 2 × Pioglitazone × Clear all
NCT01935466 2022-01-25

PROBE-PIO

Post Graduate Institute of Medical Education and Research, Chandigarh

Completed
6,107 enrolled
Genitourinary

Urinary Bladder Neoplasms, Diabetes Mellitus, Type 2

NCT02475499 2016-03-14

Incretin-based Drugs and Pancreatic Cancer

Canadian Network for Observational Drug Effect Studies, CNODES

Completed
886,172 enrolled
Gastrointestinal

Diabetes Mellitus, Type 2, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡